Prenetics Global Limited (NASDAQ:PRE) Short Interest Update

Prenetics Global Limited (NASDAQ:PRE) was the recipient of a significant increase in short interest in February. As of February 15th, there was short interest totalling 39,800 shares, an increase of 22.1% from the January 31st total of 32,600 shares. Based on an average daily volume of 14,100 shares, the short-interest ratio is presently 2.8 days. Approximately 0.5% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $9.00 price objective on shares of Prenetics Global in a report on Thursday, January 16th.

Prenetics Global Stock Performance

Shares of PRE stock opened at $4.86 on Friday. The company has a market capitalization of $59.32 million, a price-to-earnings ratio of -1.22 and a beta of -0.31. The company has a 50-day simple moving average of $5.47 and a two-hundred day simple moving average of $5.01. Prenetics Global has a 52-week low of $2.85 and a 52-week high of $7.84.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new position in shares of Prenetics Global Limited (NASDAQ:PRE) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned 0.10% of Prenetics Global as of its most recent SEC filing. 25.01% of the stock is owned by institutional investors.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.